Advanced search
Start date

Multi-target potentially antitumor agents for malignant melanoma: rational design, synthesis, and biological assays of novel benzofuroxan derivatives

Grant number: 14/14267-1
Support type:Scholarships in Brazil - Post-Doctorate
Effective date (Start): February 01, 2015
Effective date (End): January 31, 2019
Field of knowledge:Health Sciences - Medicine
Cooperation agreement: Coordination of Improvement of Higher Education Personnel (CAPES)
Principal researcher:Jose Alexandre Marzagão Barbuto
Grantee:Salomão Dória Jorge
Home Institution: Instituto de Ciências Biomédicas (ICB). Universidade de São Paulo (USP). São Paulo , SP, Brazil
Associated scholarship(s):17/01265-9 - Multi-target potentially antitumor agents for malignant melanoma: rational design, synthesis, and biological assays of novel benzofuroxan derivatives, BE.EP.PD


The study is based on previously findings observed for a series of substituted-[N'-(benzofuroxan-5-yl)methylene] benzohydrazides. These compounds, initially developed as anti-Trypanosoma cruzi agents, have shown potent cytotoxic effects against a variety of malignant tumor cells, that overexpressing MDMX protein. This protein is responsible for the deficiency of functional p53 in tumors such as melanoma, that even with wild type p53, this functionality has inhibited by MDMX. However, cancer is a multifactorial disease, which imposes the need to aggregate, in design of new drugs, different pharmacodynamic profiles capable of modulating distinct signaling pathways, in one molecule, creating drugs "multi-targets". Melanoma is the most aggressive form of skin cancer and it has been presented high resistance to many chemotherapy drugs therapeutically used, requiring the development of new therapeutic strategies. In this regard, the present proposal aims to identify antitumor drug candidates from the synthesis of a novel benzofuroxan-based library. Preliminary data obtained from lead compound, already indicate that, in addition to MDMX, BRAF protein (most promising therapeutic target in melanoma) is also affected in melanoma murine cell line B16F10. These observations indicate that these lead compound has potential to act on several tumor cell targets, suggesting that their use as structural template allied to the ligand-based drug design strategy aims the identification of novel analogs/derivatives with multi-target activity, therefore, with better probability of anticancer efficacy. (AU)

News published in Agência FAPESP Newsletter about the scholarship:
Articles published in other media outlets (0 total):
More itemsLess items

Scientific publications
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
TEIXEIRA, SARAH FERNANDES; DE AZEVEDO, RICARDO ALEXANDRE; SILVA, ARTHUR CARVALHO; BRAGA, RODOLPHO CAMPOS; JORGE, SALOMAO DORIA; MARZAGAO BARBUTO, JOSE ALEXANDRE; ANDRADE, CAROLINA HORTA; FERREIRA, ADILSON KLEBER. Evaluation of cytotoxic effect of the combination of a pyridinyl carboxamide derivative and oxaliplatin on NCI-H1299 human non-small cell lung carcinoma cells. BIOMEDICINE & PHARMACOTHERAPY, v. 84, p. 1019-1028, . (14/24455-0, 09/54599-5, 13/07273-2, 14/07341-0, 16/05351-4, 13/05396-0, 15/18528-7, 14/14267-1)
MAMBELLI, LISLEY I.; TEIXEIRA, SARAH F.; JORGE, SALOMAO D.; KAWAMURA, BARBARA; MENEGUELO, RENATO; BARBUTO, JOSE A. M.; DE AZEVEDO, RICARDO A.; FERREIRA, ADILSON K.. Phosphoethanolamine induces caspase-independent cell death by reducing the expression of C-RAF and inhibits tumor growth in human melanoma model. BIOMEDICINE & PHARMACOTHERAPY, v. 103, p. 18-28, . (13/07273-2, 17/01265-9, 16/09392-7, 16/07519-0, 15/18528-7, 14/14267-1)
FERREIRA, ADILSON KLEBER; MESQUITA PASQUALOTO, KERLY FERNANDA; KRUYT, FRANK A. E.; PALACE-BERL, FANNY; AZEVEDO, RICARDO ALEXANDRE; TURRA, KELY MEDEIROS; RODRIGUES, CECILIA PESSOA; FRANCO FERREIRA, ANA CAROLINA; CLAVIJO SALOMON, MARIA ALEJANDRA; DE SA JUNIOR, PAULO LUIZ; et al. BFD-22 a new potential inhibitor of BRAF inhibits the metastasis of B16F10 melanoma cells and simultaneously increased the tumor immunogenicity. Toxicology and Applied Pharmacology, v. 295, p. 56-67, . (09/54599-5, 13/07273-2, 14/07341-0, 13/05396-0, 14/14267-1)

Please report errors in scientific publications list by writing to: